CD47 and sarcoma: Besides GD2, newly emerging targets for pediatric cancer immunotherapy, including PD1/PD-L1 (NCT04544995, NCT04796012), B7-H3 (CD276; NCT04864821, NCT04743661), HER2 (NCT00902044, NCT04616560) and CD47 (NCT04525014, NCT04751383), have been actively investigated for pediatric sarcomas and brain tumors.